TELBIVUDINE APPROVED IN SWITZERLAND FOR CHRONIC HEPATITIS B.

Extract


TELBIVUDINE APPROVED IN SWITZERLAND FOR CHRONIC HEPATITIS B.

Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Cambridge, Mass, has announced that the Swissmedic has approved telbivudine as a new treatment for chronic hepatitis B (CHB) in compensated patients w...

See the full content of this document

Sponsored links




ver las páginas en versión mobile | web

ver las páginas en versión mobile | web

© Copyright 2012, vLex. All Rights Reserved.

Contents in vLex United States

Explore vLex

For Professionals

For Partners

Company